Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 20/20 | 0.81 |
| ▸ | CYP11B1 | P15538 | 20/20 | 0.81 |
| ▸ | CYP21A2 | P08686 | 19/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17923078 | 1.00 | CYP17A1 (0.81) | CYP17A1CYP11B1CYP21A2CYP3A4CYP19A1 | |
| SCHEMBL17974024 | 0.90 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4CYP19A1 | |
| SCHEMBL17923002 | 0.83 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4 | |
| SCHEMBL17923048 | 0.83 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4 | |
| SCHEMBL3934496 | 0.82 | CYP17A1 (0.67) | CYP17A1CYP11B1CYP21A2CYP3A4 | |
| SCHEMBL17922999 | 0.81 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4CYP19A1 | |
| SCHEMBL17922997 | 0.81 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4CYP19A1 | |
| SCHEMBL17923010 | 0.78 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4CYP19A1 | |
| SCHEMBL17923062 | 0.78 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4CYP19A1 | |
| SCHEMBL17959125 | 0.77 | CYP17A1 (0.73) | CYP17A1CYP11B1CYP21A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | claimed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | claimed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | claimed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | CYP11B1, CYP11B2, CYP21A2 | CYP17A1 6/4885CYP11B1 1/4885CYP21A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.